Stendra (avanafil)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company:

Approval Status:

Approved April 2012

Specific Treatments:

erectile dysfunction

Therapeutic Areas

Find Related Trials for The Following Conditions

General Information

Stendra (avanafil) phosphodiesterase 5 (PDE5) inhibitor. PDE5 is responsible for the degradation of cGMP, which produces smooth muscle relaxation in the corpus cavernosum and allows inflow of blood.

Stendra is specifically indicated for the treatment of erectile dysfunction.

Stendra is supplied as a tablet designed for oral administration. The recommended initial dose of Stendra is 100 mg taken approximately 30 minutes before sexual activity with or without food. The dose may be increased to 200 mg or decreased to 50 mg. Use the lowest dose that provides benefit on an as needed basis no more than once per day.

Clinical Results

FDA Approval
The FDA approval of Stendra was based on the results of 3 randomized, double-blind, placebo-controlled, parallel group trials. The trials enrolled